With these findings, we can conclude that MTAP IHC is a reliable surrogate biomarker that shows high sensitivity and specificity for detecting CDKN2A HD in diffuse gliomas as well as other CNS tumors. This evidence concerns the gene CDKN2A and central nervous system neoplasm.